Top Markets
#1 Ontology Gas Ontology Gas +26.68%
#2 Verus Coin Verus Coin +22.51%
#3 EXOD EXOD +22.08%
#4 ETHGas ETHGas +17.69%
#5 Status Status +17.53%
#6 Geodnet Geodnet +14.38%
#7 Derive Derive +12.51%
#8 Curve DAO Curve DAO +11.86%
#9 The Black Bull The Black Bull +10.06%
#10 Anvil Anvil +9.81%
Coin of the day
Ontology Gas Ontology Gas
設定
言語
日本
通貨
USD
テーマ
LianBio LianBio

LianBio

LIAN
株式のランク #25837
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
株価
$0.42275
最終同期: 2025-07-14
時価総額
$45.81M
変化（1日）
-0.89%
変化（1年）
0.00%
国
US
取引 LianBio (LIAN)

カテゴリー

Healthcare
LianBio（LIAN）の配当履歴
LianBio（証券コード：LIAN）は合計で0回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：0.00
配当利回り（TTM）：0
2026から2026までのLianBio（LIAN）の配当履歴
年間配当支払い
年 配当（株式分割調整済み） 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
年 配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴
企業 配当支払い回数 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US